Mankind Pharma IPO Financials
The Mankind Pharma IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31-Mar-20, Mankind Pharma Limited reported assets of ₹5,073.29 crore, revenue of ₹5,975.65 crore, and a profit after tax (PAT) of ₹1,056.15 crore. The company had a net worth of ₹3,485.31 crore and reserves & surplus of ₹3,436.34 crore, and total borrowings are 126.92 crore.
Revenue increased by 6.86% in 31-Mar-21 and decreased by 2.62% in 31-Dec-21 and increased by 28.29% in 31-Mar-22 and decreased by 15.04% in 31-Dec-22, while Profit After Tax (PAT) grew by 22.43% in 31-Mar-21 and declined by 2.54% in 31-Dec-21 and grew by 15.29% in 31-Mar-22 and declined by 30.08% in 31-Dec-22, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Mankind Pharma Limited Financials (₹ in Crores)
| Particular | 31-Mar-20 | 31-Mar-21 | 31-Dec-21 | 31-Mar-22 | 31-Dec-22 |
|---|---|---|---|---|---|
| Assets | 5073.29 | 6372.63 | 8043.88 | 9147.74 | 9273.75 |
| Revenue | 5975.65 | 6385.38 | 6218.29 | 7977.58 | 6777.82 |
| Profit After Tax | 1056.15 | 1293.03 | 1260.24 | 1452.96 | 1015.98 |
| Net Worth | 3485.31 | 4722 | 5965.46 | 6155.23 | 7145.89 |
| Reserve & Surplus | 3436.34 | 4674.39 | 5916.86 | 6106.06 | 7094.12 |
| Total Borrowings | 126.92 | 234.53 | 268.7 | 868.03 | 167.93 |
EPS Pre
33.20%
EPS Post
0.00%
P/E Pre
32.50
P/E (Post Issue)
0.00x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Mankind Pharma Limited?
Mankind Pharma Limited reported revenue of ₹5975.65 crore as of 31-Mar-20. Revenue figures from the Mankind Pharma IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Mankind Pharma Limited?
Mankind Pharma Limited reported a Profit After Tax (PAT) of ₹1056.15 crore as of 31-Mar-20. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Mankind Pharma Limited?
Mankind Pharma Limited has a Price-to-Earnings (P/E) ratio of 32.5x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.